- Kane Biotech (KNE) has received Decisions to Grant for two European patents for its coactiv+ technology
- The claims cover composition of matter for Kane’s proprietary formulations for treating wounds and skin infections and in personal care formulations
- coactiv+ technology destabilizes biofilms to promote an environment for fast wound healing
- Kane Biotech is focused on technologies and products that prevent and remove microbial biofilms
- Kane Biotech (KNE) is unchanged trading at $0.175 per share
Kane Biotech (KNE) has received Decisions to Grant for two European patents for its coactiv+ technology.
The claims cover the composition of matter for Kane’s proprietary formulations for treating wounds and skin infections and in personal care formulations.
A Decision to Grant means the European Patent Office has granted a patent and set the grant date.
coactiv+ technology destabilizes biofilms to promote an environment for fast wound healing.
Gordon Guay, Kane’s Chief Scientific Officer, commented,
“These patents are important additions to the existing portfolio covering Kane’s coactiv+ technology platform. Kane already had strong patent coverage in Europe, and the coverage of the coactiv+ technology is now significantly enhanced, both in terms of the scope of protection and term of protection.”
Marc Edwards, CEO of Kane Biotech, added,
“The versatility of our coactiv+ technology, as in our existing shampoo, pet water additive and wound gel applications, offers a pipeline of commercialization opportunities to license, partner or go direct to market with innovative applications to treat problems caused by biofilm proliferation.”
Kane Biotech is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
Kane Biotech (KNE) is unchanged trading at $0.175 per share as of 9:30 am ET.
